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Abstract
Background: Stage I pulmonary adenocarcinoma (PA) can offer an unfavorable prognosis. The aim of this study
was to classify the prognosis of stage I PA on the basis of the lepidic component and to confirm whether the
lepidic component can be used as a criterion for predicting the prognosis of stage I PA.
Methods: We conducted a retrospective study of patients who underwent curative surgery for stage I and IIA PA.
Stage I disease was divided into three groups on the basis of the lepidic component: group 1, ≤10 %; group 2, >10
to 50 %; and group 3, >50 %. We compared recurrence-free survival (RFS) rates among groups 1, 2, and 3, and
stage IIA disease. We also evaluated risk factors for disease recurrence with multivariate analysis.
Results: A total of 224 patients were included in our study; most patients (n = 201) had stage I disease. Three-year
RFS rates in group 1 (n = 73), group 2 (n = 75), and group 3 (n = 53) were 74.1, 90.4, and 90.0 %, respectively.
There was a significant difference in RFS between group 1 and group 2 (p = 0.009). The 3-year RFS rate in stage IIA
disease was 61.4 %. There were no significant differences in RFS between group 1 and stage IIA disease (p = 0.163).
In multivariate analysis, group 1 had the highest risk of recurrence (HR 5.806, p = 0.006) in stage I PA.
Conclusions: Stage I PA with a lepidic component ≤10 % was associated with an unfavorable prognosis that was
similar to the prognosis of stage IIA disease. The prognosis for stage I PA should not be based on general criteria,
but instead, the lepidic component should be evaluated and considered when determining disease prognosis.
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Background
Pulmonary adenocarcinoma (PA) is the most common
histologic type of primary lung cancer [1]. In 2011, the
International Association for the Study of Lung Cancer
(IASLC), the American Thoracic Society (ATS), and the
European Respiratory Society (ERS) proposed new sub-
types of adenocarcinoma. According to the new classifi-
cation system, the components of adenocarcinoma were
classified into five major histopathologic categories on
the basis of the growth pattern or shape of the tumor:
acinar, papillary, micropapillary, solid, and lepidic [2].
Among the subtypes of PA, lepidic-predominant ade-
nocarcinoma has the most favorable prognosis, and
micropapillary-predominant and solid-predominant adeno-
carcinomas have unfavorable prognoses [2, 3]. However, in
more than 90 % of PA cases, two or more components are
present and the prognosis of PA is complicated and
varies on the basis of the ratio of each histopathologic
component. After the adoption of the new classi-
fication system, many studies reported correlations
between subtypes and histopathologic components of
PA and disease prognosis [3–8].
Until now, the most important prognostic factor in
non-small cell lung cancer (NSCLC) has been its ana-
tomical stage [9]. However, recurrence can occur even
with the most favorable prognosis in stage I, which indi-
cates that other factors may affect prognosis and that
the prognosis of stage I disease varies with histopatho-
logic subtype [10]. Additionally, one study reported that
the prognosis could vary with the respective occupancy
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rates of the five histopathologic components [5]. There-
fore, stage I PA may be able to be divided into favorable
prognosis and unfavorable prognosis, which would help
to predict the disease course for patients with stage I
PA. The lepidic component is the most common com-
ponent among the five histopathologic components in
stage I PA, so it is reasonable to classify stage I PA on the
basis of the occupancy rate of the lepidic component.
The aim of this study was to confirm the usefulness of
classifying the prognosis of stage I PA on the basis of the
occupancy rate of the lepidic component. Further, we
aimed to evaluate whether the lepidic component could
be used to predict the prognosis of PA.
Methods
Patients
We conducted a retrospective chart review of 265 pa-
tients who were diagnosed with stage I and stage IIA PA
and underwent curative resection at Seoul St. Mary’s
Hospital at the Catholic University of Korea between
August 2010 and December 2013. Among 242 patients
with stage I PA, 41 patients were excluded from the
study: 25 patients who were diagnosed with adenocar-
cinoma in situ (AIS) or minimally invasive adenocar-
cinoma (MIA), 15 patients who were diagnosed with
mucinous adenocarcinoma, and 1 patient who was diag-
nosed with adenocarcinoma with neuroendocrine fea-
tures. Mucinous adenocarcinoma was excluded from our
study because it exhibits clinical, pathologic, and genetic
differences from non-mucinous adenocarcinoma and it
is classified in a new category of “variants of invasive
adenocarcinoma” in the IASLC/ATS/ERS classification
system [2]. A total of 224 patients were included in the
final study analysis: 201 patients with stage I PA and 23
patients with stage IIA PA. Cancer staging was deter-
mined according to the TNM classification system de-
fined by the American Joint Committee on Cancer [9].
This study was approved by the institutional review
board of Seoul St. Mary’s Hospital at the Catholic
University of Korea.
Histologic evaluation
All clinical specimens were examined by pathology
specialists, and their observations were recorded in path-
ology records. For the description of histopathologic
components, the occupancy ratio of each component
(lepidic, acinar, papillary, micropapillary, and solid) in
the total tumor area was measured and recorded in 5 %
increments, according to the 2011 IASLC/ATS/ERS clas-
sification system [2]. The 201 patients with stage I
disease were divided into three groups on the basis of
the occupancy ratio of the lepidic component in the
total tumor: group 1, ≤10 %; group 2, >10 to 50 %; and
group 3, >50 %.
Statistical analysis
We divided stage I disease into three groups according
to the percentage of the lepidic component, and we
compared the clinicopathologic characteristics among
the groups. We also compared characteristics between
stage I and stage IIA disease and group 1 and stage IIA
disease. For these comparisons, we used Student’s t test
for continuous variables and the χ2 test for categorical
variables. We used the analysis of variance test and the
Kruskal-Wallis H test to compare the means of the
groups. We analyzed data from the time of surgery to the
last date of follow-up, and we determined recurrence-free
survival (RFS) using the Kaplan-Meier method by calculat-
ing the cases of recurrence and death. We compared sur-
vival rates among the groups using log rank statistics. We
used the Cox proportional hazards model for the multi-
variate analysis to determine risk factors for recurrence in
patients with stage I disease. A value of p < 0.05 was con-
sidered statistically significant.
Results
The mean age of all 224 patients (stages I and IIA) was
63.7 years (range, 38–85 years), and more than half
(58.9 %) of the patients were female. Stage I disease was
divided into groups 1, 2, and 3 according to the lepidic
component; the clinical characteristics of each group are
presented in Table 1. Group 1 contained more male
patients (60.3 %) than female patients, but groups 2
and 3 contained more female patients than male pa-
tients (p < 0.001). Mean smoking amount of group 1 was
significantly higher than that of group 2 but was not sig-
nificantly different from that of group 3. There were no
differences in age, sex, or smoking history between pa-
tients with stage I and stage IIA disease. The maximum
standardized uptake value (SUVmax) of fluorodeoxyglu-
cose in positron emission tomography (PET) in group 1
was significantly higher than that of group 3 but was not
different than that of group 2. The SUVmax in stage IIA
disease was significantly higher than that in stage I disease
(p < 0.001). The SUVmax in stage IIA disease was also
significantly higher than that in group 1 (8.8 vs. 4.5;
p < 0.001). There was no difference in the rate of pulmon-
ary resection among groups 1, 2, and 3 or between stage I
and stage IIA disease. Mediastinal lymph node dissection
or sampling was conducted for every patient; there were
no differences in the average number of removed lymph
nodes among groups 1, 2, and 3, but there was a small dif-
ference between stage I and IIA disease (13.5 ± 9.5 vs.
17.7 ± 8.5, respectively; p = 0.043).
The pathologic characteristics of patients with stage
I PA, according to the lepidic component, are pre-
sented in Table 2. There was no difference in average
tumor size (p = 0.076). The incidence of pleural inva-
sion and vascular invasion were higher in groups 1
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and 2 than in group 3. The occupancy ratios of
micropapillary and acinar components were similar in
groups 1 and 2, and the occupancy ratios of solid and
papillary components were significantly higher in
group 1 than in groups 2 and 3.
The pathologic characteristics of patients in group 1
and patients with stage IIA disease are presented in
Table 3. Patients with stage IIA disease had a larger
tumor size than patients in group 1 (3.0 vs. 2.2 cm;
p = 0.005), as well as higher rates of lymphatic invasion
Table 1 Clinical characteristics of patients with pulmonary adenocarcinoma, according to disease stage and lepidic component
Stage I Stage IIA p valueb
Total Group 1 Group 2 Group 3 p valuea (n = 23)
(n = 217) (n = 73) (n = 75) (n = 53)
Age, years (±SD) 64.0 (±9.3) 64.5 (±10.3) 65.2 (±9.4) 61.8 (±7.4) 0.121 61.0 (±7.5) 0.131
Sex <0.001 0.518
Female, n (%) 117 (58.2 %) 29 (39.7 %) 59(78.7 %) 29(54.7 %) 15 (65.2)
Male, n (%) 84 (41.8 %) 44 (60.3 %) 16 (21.3 %) 24 (45.3 %) 8 (34.8)
Smoking, pack years (±SD) 8.6 (±15.6) 14.2 (±19.1) 3.8 (±10.9) 7.3 (±13.3) <0.001 5.7 (±14.7) 0.424
Laterality 0.469 0.038
Right, n (%) 137 (68.2 %) 47 (64.4 %) 55 (73.3 %) 35 (66.0 %) 10 (43.5 %)
Left, n (%) 64 (31.8 %) 26 (35.6 %) 20 (26.7 %) 18 (34.0 %) 13 (56.5 %)
SUVmax (±SD) 3.6 (±3.2) 4.5 (±3.8) 3.7 (±3.0) 2.0 (±1.8) <0.001 8.8 (±3.7) <0.001
Extent of operation 0.416 0.273
Wedge resection, n (%) 17 (8.5 %) 8 (11.0 %) 5 (6.7 %) 4 (7.5 %) 0
Segmentectomy, n (%) 10 (5.0 %) 2 (2.7 %) 6 (8.0 %) 2 (3.8 %) 0
Lobectomy, n (%) 170 (84.6 %) 62 (84.9 %) 61 (81.3 %) 47 (88.7 %) 22 (95.7 %)
Bilobectomy, n (%) 4 (2.0 %) 1 (1.4 %) 3 (4.0 %) 0 1 (4.3 %)
Surgical approach 0.475 0.692
VATS, n (%) 178 (88.6 %) 62 (84.9 %) 68 (90.7 %) 48 (90.6 %) 21 (91.3 %)
Thoracotomy, n (%) 21 (11.4 %) 11 (15.1 %) 7 (9.3 %) 5 (9.4 %) 2 (8.7 %)
Sampled lymph node, n (±SD) 13.5 (±9.5) 14.0 (±10.7) 14.0 (±9.2) 12.3(±7.9) 0.537 17.7 (±8.5) 0.043
Group 1 = lepidic component ≤10 %; group 2 = lepidic component >10 to 50 %; group 3 = lepidic component >50 %
SD standard deviation, SUVmax maximum standardized uptake value of fluorodeoxyglucose, VATS video-assisted thoracoscopic surgery
aComparison among groups 1, 2, and 3
bComparison between stage I and stage IIA
Table 2 Pathologic characteristics of patients with stage I pulmonary adenocarcinoma according to lepidic component
Group 1 Group 2 Group 3 p value
Tumor size, cm (±SD) 2.2 (±0.9) cm 2.3 (±0.9) cm 2.0 (±0.7) cm 0.076
Pleural invasion, n (%) 23 (31.9 %) 18 (24.3 %) 4 (7.5 %) 0.005
Lymphatic invasion, n (%) 21 (29.2 %) 28 (37.8 %) 9 (17.0 %) 0.039
Vascular invasion, n (%) 9 (12.5 %) 9 (12.5 %) 1 (1.9 %) 0.088
Differentiation <0.001
Mild, n (%) 15 (20.5 %) 41 (54.7 %) 48 (90.6 %)
Moderate, n (%) 49 (67.1 %) 31 (41.3 %) 5 (9.4 %)
Poor, n (%) 9 (12.3 %) 3 (4.0 %) 0 (0 %)
EGFR mutation 75.4 % 90.3 % 79.4 % 0.087
Micropapillary component, % (±SD) 3.4 (±9.4)% 3.0 (±8.5)% 0.1 (±0.7)% 0.006
Solid component, % (±SD) 15.2 (±27.9)% 1.1 (±3.7)% 0.3 (±1.6)% <0.001
Acinar component, % (±SD) 49.0 (±37.7)% 52.2 (±21.6)% 21.0 (±11.2)% <0.001
Papillary component, % (±SD) 23.8 (±22.5)% 8.7 (±18.2)% 2.9 (±6.8)% <0.001
Group 1 = lepidic component ≤10 %; group 2 = lepidic component >10 to 50 %; group 3 = lepidic component >50 %
EGFR epidermal growth factor receptor, SD standard deviation
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and vascular invasion (p < 0.001 and p = 0.001, respect-
ively). However, there were no significant differences in
the occupancy ratios of histopathologic components of
the tumor between these two groups. Specifically, the
lepidic component was not different between group 1 and
stage IIA disease (4.4 vs. 9.9 %, respectively; p = 0.095).
The median follow-up time for all patients was
720 days (range, 12–1564 days). During the follow-up
period, disease recurrence occurred in 22 (10.9 %)
patients with stage I PA and 7 (30 %) patients with stage
IIA disease. The 3-year RFS rate in stage I disease was
significantly higher than in stage IIA disease (86.3 vs.
61.4 %, respectively; p = 0.001) (Fig. 1). The 3-year RFS
rates in groups 1, 2, and 3 were 74.1, 90.4, and 90.0 %,
respectively (Fig. 2). The RFS in group 2 was signifi-
cantly higher than that in group 1 (p = 0.009), but it was
not different than that in group 3. There was no dif-
ference in 3-year RFS between group 1 and stage IIA
disease (74.1 vs. 61.4 %, respectively; p = 0.163).
The risk factors for recurrence according to multivariate
analysis are presented in Table 4. We analyzed the respect-
ive effect of each of the five histopathologic components
(%) on disease recurrence using covariate factors of age,
sex, smoking history, SUVmax, tumor size, and rates of
pleural invasion, lymphatic invasion, and vascular invasion.
Only the lepidic component was significantly related to re-
currence (hazard ratio (HR) = 0.955, 95 % CI = 0.924–0.987;
p = 0.007). A lepidic component of ≤10 % (group 1) was
associated with the highest risk of recurrence (HR = 5.806,
95 % CI = 1.666–20.238; p = 0.006).
Discussion
Most cases of PA display a mixture of five histopatho-
logic components. In the early stages of the disease, the
lepidic component is the most common component. In
our study, we divided stage I disease into three relatively
even groups on the basis of lepidic component (n = 73,
75, and 53). The 3-year RFS rates of the three groups
were 74.1, 90.4, and 90.0 %, and we demonstrated that a
higher proportion of lepidic component in the tumor
was associated with better survival. RFS was lowest with
a lepidic component ≤10 %, and the prognosis for patients
with stage I disease with a lepidic component ≤10 % was
not better than the prognosis for patients with more ad-
vanced disease.
According to the 2011 IASLC/ATS/ERS classification
criteria, acinar, papillary, micropapillary, and solid com-
ponents are classified as invasive components and differ-
entiated from lepidic components [2]. Therefore, a higher
proportion of invasive components is associated with
easier tumor invasion and an increased likelihood of
tumor progression. Consequently, the relative amounts of
components other than the lepidic component could be
important factors in determining prognosis. In the case of
stage I disease, the occupancy ratio of the lepidic compo-
nent is so high that the occupancy ratios of the other com-
ponents are relatively low. In our study, groups 1 and 2
showed different survival rates, and an evaluation of the
different components present in the tumors of these
groups indicated that only solid and papillary components
were higher in group 1 and that there were no differences
in the ratios of acinar or micropapillary components.
Many studies have reported that only micropapillary and
lepidic components are independently related to disease
recurrence, and few studies have reported that acinar,
solid, or papillary components individually affect prog-
nosis [4, 5, 11, 12]. Since we observed no difference in the
proportion of micropapillary component between groups
1 and 2, we conclude that the difference in survival was
due to the difference in lepidic component and not a dif-
ference in solid or papillary components. Further, since
the results of our multivariate analysis indicated that only
the lepidic component was found to be a risk factor for re-
currence, the low proportion of lepidic component could
be emphasized as a significant risk factor for disease
recurrence.
In NSCLC, stage IA and IB disease are differentiated
by tumor size and the presence of visceral pleural inva-
sion [9] and stage IA disease has a higher survival rate
than stage IB disease [13–15]. However, in addition to
tumor size and visceral pleural invasion that differentiate
stages IA and IB, many other factors are being investi-
gated that might influence disease prognosis, including
histopathologic components. In our study, we included
tumor size and visceral pleural invasion as covariate
Table 3 Comparison of pathologic characteristics between
patients in group 1 and patients with stage IIA pulmonary
adenocarcinoma
Group 1 Stage IIA p value
Tumor size, cm (±SD) 2.2 (±0.9)cm 3.0 (±1.3)cm 0.005
Pleural invasion, n (%) 23 (31.9 %) 9 (40.9 %) 0.298
Lymphatic invasion, n (%) 21 (29.2 %) 20 (87.0 %) <0.001
Vascular invasion, n (%) 9 (12.5 %) 11 (47.8 %) 0.001
Differentiation 0.534
Mild, n (%) 15 (20.5 %) 4 (17.4 %)
Moderate, n (%) 49 (67.1 %) 14 (60.9 %)
Poor, n (%) 9 (12.3 %) 5 (21.7 %)
EGFR mutation 75.4 % 76.2 % 0.597
Micropapillary component,
% (±SD)
3.4 (±9.4)% 5.5 (±8.9)% 0.378
Solid component, % (±SD) 15.1 (±27.9)% 15.7 (±29.5)% 0.936
Acinar component, % (±SD) 49.0 (±37.7)% 48.3 (±28.5)% 0.927
Papillary component, % (±SD) 23.84 (±33.5)% 17.1 (±22.7)% 0.296
Lepidic component, % (±SD) 4.4 (±4.6)% 9.9 (±15.0)% 0.095
Group 1 = stage I disease with lepidic component ≤10 %
EGFR epidermal growth factor receptor, SD standard deviation
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factors in the multivariate analysis and the percentage of
lepidic component was found to influence prognosis. In
group 1, specifically, a low percentage of lepidic compo-
nent was determined to be a risk factor for recurrence
with an HR of 5.8. Therefore, this criterion could be
used to determine prognosis as well as differentiate stage
IA from stage IB disease.
When we examined the clinicopathologic characteris-
tics of group 1, we observed that this group contained
more males and more people with a smoking history
than groups 2 and 3, as well as stage IIA disease. It
shows that the characteristics of patients in group 1
were different than those of patients with other types of
adenocarcinoma. We observed no significant differences
between groups 1 and 2 when we evaluated other known
prognostic factors such as SUVmax, tumor size, per-
centage of micropapillary component, and rates of
pleural invasion, lymphatic invasion, and vascular inva-
sion [3, 16–20]. However, there was a difference in RFS
between groups 1 and 2, which indicated that the differ-
ence in prognosis was due to the difference in the lepidic
component between the groups.
The lepidic component represents only a small pro-
portion of tumors in stage II disease, so it is only pos-
sible to differentiate stage I disease according to the
lepidic component [5]. The results of our comparison of
clinicopathologic characteristics between group 1 and
stage IIA disease showed that there was significantly
more lymphatic invasion and vascular invasion and
tumor size was larger in stage IIA disease. Tumor size
and lymphovascular invasion are important prognostic
factors for PA [16–19]. SUVmax, which is a known
prognostic factor in early lung cancer, was also sig-
nificantly higher in stage IIA disease [3, 20]. Moreover,
21 (91.3 %) patients with stage IIA disease had lymph
node metastasis. On the basis of these results alone, the
prognosis of stage IIA could be assumed to be worse
than that of group 1. However, we observed no differ-
ence in the distributions of histopathologic components
or 3-year RFS between group 1 and stage IIA disease.
Therefore, we inferred that the prognosis of stage I disease
could be similar to that of stage IIA disease if the histo-
pathologic components showed similar patterns, even if
the pathologic features are worse in stage IIA disease.
In this study, we evaluated RFS instead of overall
survival because, in the case of stage I disease, more
patients die from other causes than from the relevant
cancer during the follow-up period [3]. Also, RFS is a
more accurate measurement of survival analysis, since it
reflects the biological behavior of the cancer rather than
death due to unrelated factors. Further, since we only
included relatively recent data in our analysis, we were
only able to use 3-year survival data to evaluate disease
prognosis. This restriction was necessary because the
Fig. 1 Three-year recurrence-free survival of patients with stage I and stage IIA pulmonary adenocarcinoma
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institution at which the authors practice established
video-assisted thoracoscopic surgery (VATS) as the gen-
eral method of operation beginning in August 2010;
since that time, this type of operation has been per-
formed on the majority of patients at the institution and
full mediastinal lymph node dissection has been per-
formed. In addition, we determined that 3-year RFS was
sufficient to examine prognosis since, in PA, most cases
of postoperative recurrence occur within 2 years and
cancer that recurs after 2 years has a high likelihood of
being metachronous cancer [21].
This study has several limitations that should be con-
sidered. First, we used a retrospective study design.
Second, we obtained the data from a single institution
and the number of cases was relatively small. However,
most studies that have evaluated the histopathologic
classification of stage I PA included approximately 200
cases. Compared to these studies, the 217 patients with
stage I disease included in our study do not comprise a
small sample size [10, 22–27]. Of course, more accurate
results could be obtained if the analysis and comparison
were made with a larger patient sample. Third, we used
recent data (2010 to 2013), so only short-term follow-up
information was available and only 3-year survival evalu-
ation was possible. However, as mentioned, most cases
Table 4 Multivariate analysis of risk factors for recurrence of
pulmonary adenocarcinoma
HR 95 % CI p value
Age 0.960 0.911–1.011 0.120
Sex 0.678 0.161–2.853 0.597
Smoking history 1.006 0.974–1.039 0.714
SUVmax 1.011 0.860–1.189 0.893
Tumor size 1.456 0.715–2.965 0.300
Pleural invasion 0.469 0.117–1.874 0.284
Lymphatic invasion 2.487 0.677–9.134 0.170
Vascular invasion 1.496 0.321–6.960 0.608
Lepidic component (%) 0.955 0.924–0.987 0.007
Micropapillary component (%) 1.040 0.991–1.092 0.114
Acinar component (%) 1.012 0.993–1.032 0.209
Papillary component (%) 1.016 0.994–1.038 0.155
Solid component (%) 0.982 0.927–1.041 0.546
Lepidic component ≤10 % 5.806 1.666–20.238 0.006
CI confidence interval, HR hazard ratio, SUVmax maximum standardized uptake
value of fluorodeoxyglucose
Fig. 2 Three-year recurrence-free survival among three groups of patients with stage I pulmonary adenocarcinoma and patients with stage IIA
pulmonary adenocarcinoma. Group 1 = stage I disease with lepidic component ≤10 %; group 2 = stage I disease with lepidic component >10 %
to 50 %; group 3 = stage I disease with lepidic component >50 %
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of recurrence of lung cancer occur within 2 years, and
we judged that 3-year RFS was suitable for the determin-
ation of prognosis [21]. More accurate results could be
obtained if more data were available from progressive
observations over a longer period of time.
Conclusions
In conclusion, recurrence often occurs in stage I PA,
even after curative surgery. Specifically, recurrence is
likely in cases in which the lepidic component of the
tumor is less than or equal to 10 %. Further, in stage I
disease with a low lepidic component, recurrence rates
are not significantly different than those of stage IIA
disease and generally applied stage I prognoses should
not be expected. Adjuvant treatment, which is often
performed in stage II disease, can be considered for
stage I disease with a low lepidic component. Future
studies that collect data from larger sample sizes will
confirm the relationships between the histopathologic
components of PA and disease prognosis.
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